A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of GS-4774 in Combination With Tenofovir Disoproxil Fumarate (TDF) for the Treatment of Subjects With Chronic Hepatitis B and Who Are Currently Not on Treatment

Trial Profile

A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of GS-4774 in Combination With Tenofovir Disoproxil Fumarate (TDF) for the Treatment of Subjects With Chronic Hepatitis B and Who Are Currently Not on Treatment

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Apr 2017

At a glance

  • Drugs GS 4774 (Primary) ; Tenofovir disoproxil fumarate (Primary)
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 27 Jan 2017 Planned End Date changed from 1 Jun 2018 to 13 Jun 2018.
    • 12 May 2016 According to a GlobeImmune media release, 48-week results are expected to be available in the second half of 2016.
    • 04 Apr 2016 Planned End Date changed from 1 Aug 2018 to 1 Jun 2018 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top